Journal profile · Radiology, Nuclear Medicine & Medical Imaging
Cancer Biotherapy and Radiopharmaceuticals
ISSN 1084-9785 · eISSN 1557-8852 · Mary Ann Liebert Inc. · UNITED STATES · Bimonthly · Founded 1996
Cancer Biotherapy and Radiopharmaceuticals: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.67; hybrid open access; review about 3 months (community reports); community-reported acceptance: about 95%; 88 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Biotherapy and Radiopharmaceuticals is published by Mary Ann Liebert Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Radiopharmaceutical Chemistry and Applications, Medical Imaging Techniques and Applications and Monoclonal and Polyclonal Antibodies Research, together about 32.6% of its articles. Its main subfields are Radiology, Nuclear Medicine and Imaging. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
Source: LetPub
Research area (LetPub): Radiology, Nuclear Medicine & Medical Imaging
Editor-in-chief Ekaterina DadachovaPublisher website
Editorial board by country: 1 in mainland China (about 5%); most named United States 9, Italy 4, India 3, Mainland China 1, Canada 1 (22 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Radiopharmaceutical Chemistry and ApplicationsMedicine19.8%
- Medical Imaging Techniques and ApplicationsMedicine6.6%
- Monoclonal and Polyclonal Antibodies ResearchMedicine6.3%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology6.1%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.2%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology5%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.6%
- Cancer Immunotherapy and BiomarkersMedicine3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.67LetPub ·
- Impact factor (publisher)
- 1.7Publisher website ·
- 5-year impact factor (publisher)
- 2.4Publisher website ·
- CiteScore 2026-06
- 5.9LetPub ·
- SJR 2026-06
- 0.5LetPub ·
- SNIP 2026-06
- 0.49LetPub ·
- h-index
- 55LetPub ·
- h-index
- 77OpenAlex ·
- i10-index
- 1,316OpenAlex ·
- 2-year mean citedness
- 1.06OpenAlex ·
- Self-citation rate
- 5.9%LetPub ·
- Share of gold OA articles
- 7.65%LetPub ·
Volume
- Articles per year
- 83LetPub ·
Articles by year OpenAlex count · 2,523 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 62 | 1 | 7 |
| 2025 | 88 | 3 | 81 |
| 2024 | 68 | 16 | 142 |
| 2023 | 37 | 6 | 134 |
| 2022 | 51 | 7 | 345 |
| 2021 | 121 | 22 | 928 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 95%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Mary Ann Liebert Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1996
- ISSN
- 1084-9785
- Electronic ISSN
- 1557-8852
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cancer Biotherapy and Radiopharmaceuticals
What CAS zone is Cancer Biotherapy and Radiopharmaceuticals in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Biotherapy and Radiopharmaceuticals is in Zone 4 of Medicine, and in Zone 4 of the minor category Medicine, Research & Experimental / Oncology / Pharmacology & Pharmacy / Radiology, Nuclear Medicine & Medical Imaging. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Biotherapy and Radiopharmaceuticals?
The latest impact factor listed by LetPub is 1.67; CiteScore 5.9, h-index 77.
How long does peer review take at Cancer Biotherapy and Radiopharmaceuticals?
Authors report an average review time of about 3 months; the community-reported acceptance is “about 95%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Cancer Biotherapy and Radiopharmaceuticals based?
Of the 22 board members whose country the journal's board page names, 1 (about 5%) are in mainland China; the countries named most often are United States (9), Italy (4) and India (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Biotherapy and Radiopharmaceuticals?
According to LetPub and DOAJ records, Cancer Biotherapy and Radiopharmaceuticals is indexed in SCIE and Scopus.
Is Cancer Biotherapy and Radiopharmaceuticals open access, and what is the APC?
Cancer Biotherapy and Radiopharmaceuticals is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .